Akonni Biosystems to aid USARMRIID in fighting bioweapons

Akonni Biosystems recently signed a licensing agreement with the United States Army Medical Research Institute of Infectious Diseases to aid in fighting potential bioweapons.

Under the agreement, Akonni, a molecular diagnostics company, will have full access, under patents owned or licensed by USAMRIID, to the nucleic acid sequences of some of the world’s most deadly biological agents.

Having such access should allow Akonni to rapidly commercialize a family of highly complex tests for research and in vitro diagnostics. The financial terms of the agreement have not been disclosed at this time.

“We are excited to partner with USAMRIID on developing a series of low-cost, multiplex testing products to protect our war-fighters, first responders and citizens from many of the most dangerous bio-threat agents known to man,” Akonni CEO Dr. Charles Daitch said. “Our engineering, manufacturing and quality systems expertise coupled with USAMRIID’s expertise in biological assay development creates a very powerful combination for delivering a new generation of rapid, low-cost bio-security products to the marketplace.”

Akonni intends to continue to develop a product family that expands its current offerings far beyond traditional infectious diseases like antiviral influenza. Its new market will be in the global security field, where detection of agents in a low-cost environment is critical.